Nachricht vom 23.07.2021 | 07:00
Solid second quarter for the biotech industry - BB Biotech raised its allocation to promising small and mid caps
DGAP-News: BB BIOTECH AG / Key word(s): Half Year Report/Interim Report
23.07.2021 / 07:00
Media release of July 23, 2021
Interim report of BB Biotech AG as at June 30, 2021
Solid second quarter for the biotech industry - BB Biotech raised its allocation to promising small and mid caps
Inflation moved higher during the second quarter as the economic recovery gathered steam, triggering temporary outflows of investor capital from growth sectors. Central banks signaled that the rise in inflation would be short-lived, after which capital began to flow back into tech and healthcare stocks. BB Biotech shares returned 5.8% in CHF and 6.1% in EUR in the second quarter of 2021. Their total return for the first half of 2021 including the dividend payout was 22.2% in CHF and 21.3% in EUR. BB Biotech took profits in Alexion, Biogen, Mode
Germany
Italy
Switzerland
Schaffhausen
Italian
German
Swiss
Tanja-chicherio
Claude-mikkelsen
Susan-galbraith
Esperion-nexlizet-nexletol
Silvia-schanz